Upside – $JAGX +35% (announces a special stock dividend) – $OPCH +21% (reported takeover talks value the transaction at more than $5B including debt) – $APOG +20% (Q2 beat sharply and the FY adjusted EPS and sales outlooks were raised above expectations) – CEG +9.3% (reports of a potential $1B-plus hyperscaler nuclear-power agreement) – $PENN …
Read in context ›Vaxcyte Stock (PCVX)
Track Vaxcyte stock through TheStreet Pro's latest coverage, including articles, Daily Diary mentions, TheStreet Pro portfolio activity, contributor watchlist signals, and Pro price levels.
PCVX
Vaxcyte
healthcare
At close
$71.38
â–² +6.36 (+9.79%)
Oct 9, 4:00 PM ET
After-hours
$71.35
â–¼ -0.03 (-0.04%)
Oct 9, 7:54 PM ET
Market Cap
$9.67B
P/E Ratio
—
1Y Return
+69.99%
EPS (TTM)
-$7.71
Read the latest TheStreet Pro articles mentioning Vaxcyte, including market roundups, portfolio updates, trade ideas, and investing analysis.
Articles
0 articlesNo articles mentioning PCVX yet.
Daily Diary Mentions
2 mentionsUpside, Downside Moves in the Morning Upside, Downside Movers in the Morning Upside – $ALEC +58% (global AL050 license brings $100M upfront, up to $1.17B in milestones and extends the cash runway into 2029) – $PCVX +55% (VAX-31 OPUS-1 pivotal Phase 3 trial met all prespecified primary endpoints with a safety profile comparable to existing vaccines) – $PTC +36% (agrees to a $205-a-share all-cash takeover valuing its …
Read in context ›